Interferon-γ and Celecoxib Inhibit Lung-tumor Growth Through Modulating M2/M1 Macrophage Ratio in the Tumor Microenvironment

Overview

Journal Drug Des Devel Ther

Specialty Pharmacology

Date 2014 Oct 7

PMID 25284985

Citations 25

Authors

Fuqiang Ren

Mingyu Fan

Jiandong Mei

Yongqiang Wu

Chengwu Liu

Qiang Pu

Zongbing You

Lunxu Liu

Affiliations

Soon will be listed here.

Abstract

Tumor-associated macrophages play an important role in tumor growth and progression. These macrophages are heterogeneous with diverse functions, eg, M1 macrophages inhibit tumor growth, whereas M2 macrophages promote tumor growth. In this study, we found that IFNγ and/or celecoxib (cyclooxygenase-2 inhibitor) treatment consistently inhibited tumor growth in a mouse lung cancer model. IFNγ alone and celecoxib alone increased the percentage of M1 macrophages but decreased the percentage of M2 macrophages in the tumors, and thus the M2/M1 macrophage ratio was reduced to 1.1 and 1.7 by IFNγ alone and celecoxib alone, respectively, compared to the M2/M1 macrophage ratio of 4.4 in the control group. A combination of IFNγ and celecoxib treatment reduced the M2/M1 macrophage ratio to 0.8. Furthermore, IFNγ and/or celecoxib treatment decreased expression of matrix metalloproteinase (MMP)-2, MMP-9, and VEGF, as well as the density of microvessels in the tumors, compared to the control group. This study provides the proof of principle that IFNγ and/or celecoxib treatment may inhibit lung-tumor growth through modulating the M2/M1 macrophage ratio in the tumor microenvironment, suggesting that IFNγ and celecoxib have potential to be further optimized into a new anticancer therapy.

Citing Articles

Dynamic changes in macrophage morphology during the progression of choroidal neovascularization in a laser-induced choroidal neovascularization mouse model.

Xu N, Sun T, Wang Y, Tong X, Lu S, Yang F BMC Ophthalmol. 2023; 23(1):401.

PMID: 37803306 PMC: 10559478. DOI: 10.1186/s12886-023-03141-7.

Regulatory cells and the effect of cancer immunotherapy.

Iglesias-Escudero M, Arias-Gonzalez N, Martinez-Caceres E Mol Cancer. 2023; 22(1):26.

PMID: 36739406 PMC: 9898962. DOI: 10.1186/s12943-023-01714-0.

Relationship between Tumor Infiltrating Immune Cells and Tumor Metastasis and Its Prognostic Value in Cancer.

Li H, Wang S, Lian Z, Deng S, Yu K Cells. 2023; 12(1).

PMID: 36611857 PMC: 9818185. DOI: 10.3390/cells12010064.

Biological implications and clinical potential of invasion and migration related miRNAs in glioma.

Guo X, Jiao H, Cao L, Meng F Front Integr Neurosci. 2022; 16:989029.

PMID: 36479040 PMC: 9720134. DOI: 10.3389/fnint.2022.989029.

Integration of local and systemic immunity in ovarian cancer: Implications for immunotherapy.

Rajtak A, Ostrowska-Lesko M, Zak K, Tarkowski R, Kotarski J, Okla K Front Immunol. 2022; 13:1018256.

PMID: 36439144 PMC: 9684707. DOI: 10.3389/fimmu.2022.1018256.

References

Zhang W, Zhu X, Sun H, Xiong Y, Zhuang P, Xu H . Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res. 2010; 16(13):3420-30. DOI: 10.1158/1078-0432.CCR-09-2904. View

Lanciotti M, Masieri L, Raspollini M, Minervini A, Mari A, Comito G . The role of M1 and M2 macrophages in prostate cancer in relation to extracapsular tumor extension and biochemical recurrence after radical prostatectomy. Biomed Res Int. 2014; 2014:486798. PMC: 3967497. DOI: 10.1155/2014/486798. View

Topalian S, Hodi F, Brahmer J, Gettinger S, Smith D, Mcdermott D . Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366(26):2443-54. PMC: 3544539. DOI: 10.1056/NEJMoa1200690. View

Mantovani A, Sica A, Locati M . Macrophage polarization comes of age. Immunity. 2005; 23(4):344-6. DOI: 10.1016/j.immuni.2005.10.001. View

Gordon S . Alternative activation of macrophages. Nat Rev Immunol. 2003; 3(1):23-35. DOI: 10.1038/nri978. View

DeNardo D, Brennan D, Rexhepaj E, Ruffell B, Shiao S, Madden S . Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011; 1(1):54-67. PMC: 3203524. DOI: 10.1158/2159-8274.CD-10-0028. View

Zhang H, Li Z, Wang K . Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo. Oncol Rep. 2014; 31(4):1954-60. DOI: 10.3892/or.2014.3026. View

Zhang M, He Y, Sun X, Li Q, Wang W, Zhao A . A high M1/M2 ratio of tumor-associated macrophages is associated with extended survival in ovarian cancer patients. J Ovarian Res. 2014; 7:19. PMC: 3939626. DOI: 10.1186/1757-2215-7-19. View

Ma J, Liu L, Che G, Yu N, Dai F, You Z . The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer. 2010; 10:112. PMC: 2851690. DOI: 10.1186/1471-2407-10-112. View

10.

Dai F, Liu L, Che G, Yu N, Pu Q, Zhang S . The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer. BMC Cancer. 2010; 10:220. PMC: 2880994. DOI: 10.1186/1471-2407-10-220. View

11.

Mantovani A, Sica A, Locati M . New vistas on macrophage differentiation and activation. Eur J Immunol. 2006; 37(1):14-6. DOI: 10.1002/eji.200636910. View

12.

Kantoff P, Higano C, Shore N, Berger E, Small E, Penson D . Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363(5):411-22. DOI: 10.1056/NEJMoa1001294. View

13.

Ledford H . Cancer treatment: The killer within. Nature. 2014; 508(7494):24-6. DOI: 10.1038/508024a. View

14.

Galdiero M, Garlanda C, Jaillon S, Marone G, Mantovani A . Tumor associated macrophages and neutrophils in tumor progression. J Cell Physiol. 2012; 228(7):1404-12. DOI: 10.1002/jcp.24260. View

15.

Rahman M, Dhar D, Yamaguchi E, Maruyama S, Sato T, Hayashi H . Coexpression of inducible nitric oxide synthase and COX-2 in hepatocellular carcinoma and surrounding liver: possible involvement of COX-2 in the angiogenesis of hepatitis C virus-positive cases. Clin Cancer Res. 2001; 7(5):1325-32. View

16.

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View

17.

Weidner N . Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat. 1995; 36(2):169-80. DOI: 10.1007/BF00666038. View

18.

Hung T, Chan J, Russell P, Power C . Zoledronic acid preserves bone structure and increases survival but does not limit tumour incidence in a prostate cancer bone metastasis model. PLoS One. 2011; 6(5):e19389. PMC: 3095598. DOI: 10.1371/journal.pone.0019389. View

19.

Pander J, Heusinkveld M, der Straaten T, Jordanova E, Baak-Pablo R, Gelderblom H . Activation of tumor-promoting type 2 macrophages by EGFR-targeting antibody cetuximab. Clin Cancer Res. 2011; 17(17):5668-73. DOI: 10.1158/1078-0432.CCR-11-0239. View

20.

Lipson E, Sharfman W, Drake C, Wollner I, Taube J, Anders R . Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin Cancer Res. 2012; 19(2):462-8. PMC: 3548952. DOI: 10.1158/1078-0432.CCR-12-2625. View